Product Information
ZITUVIO 25 MG TABLET is a brand product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $10.0542 per EA under NDC 70710124003. Its NADAC has been published 72 times since May 21, 2025.
FDA first approved this application on Oct 18, 2023.
Strength
25 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710124003
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SITAGLIPTINApproval Type
New Drug (NDA)
FDA Application
NDA211566FDA Approved
10/18/2023
On Market Since
11/30/2023
Pharmacological Classes
Price Statistics
The NADAC for ZITUVIO 25 MG TABLET has been published 72 times since May 21, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.0542 per EA |
|---|---|
| All-time high | $10.1125 (Jun 11, 2025) |
| All-time low | $10.0279 (Aug 20, 2025) |
| 52-week high | $10.0646 |
| 52-week low | $10.0397 |
| Median price | $10.0553 |
| Average price | $10.0583 |
| Largest weekly change | -0.4% (Jul 23, 2025) |
| Weeks tracked | 72 |
| Tracking since | May 21, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sitagliptin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sitagliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZITUVIO 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZITUVIO 25 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $10.0542 per EA (NDC 70710124003), effective Sep 30, 2026.
How has the price of ZITUVIO 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZITUVIO 25 MG TABLET has held within roughly two percent of its current level. It has been tracked across 72 weekly CMS publications since May 21, 2025.
What are the highest and lowest recorded NADAC prices for ZITUVIO 25 MG TABLET?
Since May 21, 2025, the NADAC for ZITUVIO 25 MG TABLET has ranged from a low of $10.0279 (Aug 20, 2025) to a high of $10.1125 (Jun 11, 2025), with a median of $10.0553 per EA.
Are there cheaper alternatives to ZITUVIO 25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ZITUVIO 25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZITUVIO 25 MG TABLET?
ZITUVIO 25 MG TABLET (NDC 70710124003) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a brand product.